Previous studies have demonstrated that the methylation of the MGMT promoter, which leads to the silencing of MGMT transcription, has a significant impact on the response to TMZ-based therapy and the survival in patients with newly diagnosed glioblastoma [6], [11], [12]. The gene discussed is MGMT; the disease is glioblastoma.